Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma

UCI Authors: Fruehauf JP,Lutzky J,McDermott DF,Brown CK,Meric JB,Rosbrook B,Shalinsky DR,Liau KF,Niethammer A... http://t.co/gHIil8w3

[VEGF] Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endoth... http://t.co/26kGGOtM PM